Research Offers Hope for HIV+ Cancer Patients
A proposed new treatment to help HIV/AIDS patients suffering from Kaposi’s sarcoma, the most common form of cancer in people with HIV, is now one step closer to becoming a reality.
Charles S. Craik, PhD, a professor in the UCSF School of Pharmacy, has received new support to develop his latest research on the herpes virus that causes Kaposi’s sarcoma through a $100,000 T1 Translational Catalyst Award offered through UCSF’s Clinical and Translational Science Institute (CTSI). Craik, who works in the Department of Pharmaceutical Chemistry, is known for leading the team that identified HIV protease inhibitors in the late 1980s.
An especially promising aspect of Craik’s research is its potential to also lead to a new treatment for the cytomegalovirus (CMV), a related herpes virus that can lead to pneumonia and gastrointestinal, retinal and neurological diseases in infants and in transplant recipients and other immunocompromised individuals.
Read more at UCSF.edu
We hope the conversations that take place on ctsi.ucsf.edu will be energetic and constructive.
To make sure we all stay on-topic, all posts will be reviewed for readability and clarity by our editors and may be edited for clarity, length, and relevance.
We ask that commentators adhere to the following guidelines.
- No selling of products or services. This is an ad-free zone.
- No offensive language and ad hominem attacks. Criticize ideas, not the people behind them.
- No multimedia. If you want to share outside sources, please link to them, don't paste them in.
Once postings are published, they are public, and we take no responsibility for how they might be disseminated or republished on the web or in other media.
All postings become the property of ctsi.ucsf.edu.